AMRI Announces Funded Research Collaboration With Navigen

AMRI's Global Integrated Drug Discovery Platform Supports Discovery of New Drug Therapies

Albany, NY - AMRI announced today that it has initiated a research collaboration with Navigen Pharmaceuticals, Inc. focused on the development of new drug therapies.

Under the terms of the multi-year agreement, AMRI will provide fully integrated drug discovery services including assay development, screening, in vitro ADMET, computer-aided drug discovery (CADD) and medicinal chemistry.

“AMRI has a proven track record of success working with biotech companies such as Navigen,” said Michael P. Trova, Ph.D., senior vice president, chemistry. Our ability to execute integrated biology and chemistry services under the helm of an experienced project manager ensures best practices are applied to the delivery of high quality preclinical candidates with a strong intellectual property position to our customers. We look forward to the opportunity to work with Navigen to help advance their early drug discovery efforts.”

About AMRI
Founded in 1991, Albany Molecular Research, Inc. provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S. , Europe, and Asia , AMRI provides customers with a wide range of services, technologies and cost models.

SOURCE: Curia